The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH Authors: Beatrice Foglia, Jessica Nurcis, Marta Signorini, Erica Novo, Claudia Bocca, Stefania Cannito, Maurizio Parola Published: 2026 ABSTRACT Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the emerging leading cause of Chronic Liver Disease (CLD) worldwide, with a global prevalence of approximately 30% in the general population that parallels global rates of obesity and Type 2 Diabetes (T2D). Although two drugs (Resmetirom and Semaglutide) have been recently approved for clinical use, their ability to block or slow down disease progression to metabolic dysfunction-associated Steatohepatitis (MASH) and liver fibrosis is limited to a subset of patients, and no data are available at present for the efficacy of these drugs in compensated cirrhosis or in relation to hepatocellular carcinoma (HCC) development. Moreover, there is a lack of reliable biomarkers able to identify MASH patients at risk of disease progression and/or HCC development. In line with the knowledge that pro-inflammatory cytokines play a key role in MASLD/MASH progression and HCC development, in this review, we will discuss the role in this disease and other CLDs of Oncostatin M (OSM), a cytokine belonging to the IL6 family, and of pathways involving OSM and its receptor β (OSM/OSMRβ axis). OSM and related pathways are emerging as selective in sustaining disease progression by promoting chronic inflammation and fibrogenesis. The OSM/OSMRβ axis is proposed to be involved in MASH-related HCC development by affecting proliferation, angiogenesis, invasiveness and metastasis as well as by reshaping the MASH-related tumor immune microenvironment. OSM and the OSM/OSMRβ axis are emerging as a candidate biomarker and putative MASH-related therapeutic target. 1. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Relevant Disease Worldwide Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the emerging leading cause of Chronic Liver Disease (CLD) worldwide, with epidemiological studies indicating that MASLD affects approximately 1 billion individuals globally (including adults, children and adolescents) in the general population [1]. A recent meta-analysis performed by pooling MASLD prevalence estimates and ultrasound-defined MASLD revealed an overall global prevalence of approximately 30.0% [1]; moreover, in the USA, Europe and Southeast Asia, MASLD prevalence is predicted to further rise by 2030, affecting more than 400 million individuals in these areas [2]. Such a high global prevalence of MASLD is expected to coincide with rising rates of obesity and Type 2 Diabetes (T2D) worldwide, with approximately 65% of T2D patients having MASLD. This metabolic disease is currently viewed as the hepatic manifestation of metabolic syndrome and is associated with additional metabolic risk factors [3]. MASLD can be diagnosed on the basis of the following major evidence: hepatic steatosis upon histopathological analysis of liver biopsies, or imaging techniques indicating the presence of more than 5% of hepatocytes with an accumulation of triglycerides (TGs) in association with at least one or more cardiometabolic risk factors (including altered levels of body mass index (BMI), fasting glucose, blood pressure, plasma triglycerides, or plasma HDL/cholesterol). Diagnosis of MASLD also requires that these patients consume little or no alcohol, and that the involvement of other metabolic, hereditary, toxic- or drug-induced causes of fatty liver can be excluded [4]. 1.1. MASLD as a Progressive Chronic Liver Disease: From Simple Steatosis to Cirrhosis and Hepatocellular Carcinoma (HCC) Development MASLD, according to histopathological analyses, is currently defined as a dynamic spectrum of conditions ranging from simple steatosis to the progressive form of metabolic dysfunction-associated steatohepatitis (MASH) [5]. Approximately 75–80% of MASLD patients present only simple steatosis, which is usually considered a non-progressive or slowly progressive condition, although paired-biopsy longitudinal studies have shown that a subset of patients with simple steatosis can progress to MASH and advanced fibrosis [6]. The diagnosis of MASH implies morphological evidence of steatosis associated with aspects of hepatocyte injury and death (including ballooning, apoptosis and other kinds of cell death such as necroptosis, pyroptosis and ferroptosis) as well as lobular and/or portal inflammatory infiltrate and a variable degree of fibrosis. MASH patients are at risk of fibrogenic progression towards a more advanced stage of CLD and cirrhosis; although the natural course of MASLD is inconstant and characterized by bidirectional and concordant changes in both disease activity and fibrosis stage, MASH-associated liver fibrosis is considered the strongest predictor for disease-specific progression and mortality [6]. Finally, cirrhotic MASH patients carry a 1.3–2% per year risk of developing hepatocellular carcinoma (HCC), and overall MASH is currently indicated as the most rapidly growing cause of HCC in liver transplant candidates [7,8]. HCC accounts for approximately 85–90% of all primary liver cancers, representing the sixth most common cancer and the third leading cause of cancer-related death worldwide. HCC is often diagnosed at an advanced stage in most patients (50–60%), with survival at five years from diagnosis usually less than 30% due to the insufficient results obtained with conventional therapeutic approaches (i.e., surgical resection or, for unresectable tumors, transarterial chemoembolization (TACE), or systemic treatments), with some improvement more recently related to the use of immune-checkpoint inhibitors (ICIs) in viral patients [1,5,7,8,9,10,11]. Unfortunately, the overall scenario is even more unsatisfying for MASLD/MASH patients. In addition to the very high prevalence of MASLD in the general population, one should consider the following: (i) Unlike other etiologies, in which HCC mainly develops in cirrhotic patients, MASH-related HCC is now increasingly reported in non-cirrhotic patients [8,9]. (ii) At present, only two drugs, Resmetirom and Semaglutide, have been conditionally approved for the treatment of MASH patients with F2/F3 fibrosis; both drugs were able to reduce fibrosis and led to MASH resolution in a subset of patients (with Semaglutide being more efficient than Resmetirom), but whether they may be clinically useful in compensated cirrhosis or against HCC development is still unknown (see ref. [12] for a review dedicated to emerging therapies for MASLD/MASH). (iii) Other persisting challenges are represented by the lack of validated biomarkers able to identify MASH patients at risk of disease progression and/or HCC development, ongoing reliance on biopsy-based surrogates, high placebo response rates and heterogeneity in disease biology and clinical course. (iv) Available data suggest that ICIs may be less efficient in MASLD/MASH-related HCC than for hepatic tumors of different etiology (particularly vs. HCC patients with viral etiology) [13]; along these lines, murine studies of MASH-HCC reported a lack of efficacy of ICIs that was related to changes in tumor microenvironment (i.e., decrease in antitumor CD4+ and CD8+ T cells, exhaustion of PD-1+ CD8+ T cells, aberrant CD8+ T-cell activation within the tumor exerting cytotoxicity vs. hepatocytes). However, data from clinical cohorts show mixed findings in relation to ICI efficacy in MASH-HCC, and caution is needed when extrapolating preclinical data to MASH patients [13,14]. 1.2. The Metabolic and Pathophysiological Basis of MASLD/MASH: Of Fatty Acid, Carbohydrate and Liver X Receptors (LXR)/Cholesterol Metabolism MASLD is closely linked to obesity and T2D [3,6,10,15], and the resulting metabolic changes reflect an imbalance in liver energy metabolism, due to excessive delivery of lipids and other substrates. Excess nutrients overwhelm the liver’s capacity to oxidize these substrates or export them after incorporation into very-low-density lipoproteins (VLDLs). The major metabolic and pathophysiological determinants leading to MASLD can be summarized as follows: (i) Increased consumption of foods containing high levels of lipids, particularly saturated fatty acids (FAs), and/or carbohydrates such as mono- and disaccharides, particularly fructose and sucrose, which in turn can activate de novo lipogenesis (DNL). (ii) The development of insulin resistance (IR) in expanded and inflamed white adipose tissue (WAT), resulting in increased lipolysis and increased fatty acid delivery to the liver. (iii) The development of hepatic IR, which is strictly related to peripheral IR and becomes more severe during disease progression. This results in insufficient suppression of hepatic gluconeogenesis, decreased glycogen synthesis and the redirection of glucose into lipogenic pathways. (iv) Development of lipid deposition in skeletal muscle, with the consequent development of local IR [3,6,10,15]. The following interconnected mechanisms represent the major contributors to the development of steatosis: (i) Increased DNL, resulting mainly from the increased delivery of glucose and other carbohydrates such as fructose to the liver and closely associated with hyperinsulinemia. This, in turn, leads to (ii) the up-regulation of key genes encoding for lipogenic enzymes that regulate DNL, mainly through the involvement of sterol regulatory element binding-protein 1c (SREBP1c), carbohydrate response element binding-protein (ChREBP), LXR or peroxisome proliferator-activated receptor γ (PPARγ). (iii) Increased delivery of FA to the liver results in an increased esterification of fatty acids into TG, involving increased diacylglycerol (DG) formation and enhanced activity of diacylglycerol O-acyltransferase 2 (DGAT2) [10,15,16]. In response to the increased FA load and TG formation, hepatocytes face several metabolic limitations: (i) decreased intrahepatic lipolysis, (ii) decreased or insufficient TG export via VLDL, and (iii) insufficient FA metabolism through mitochondrial and/or peroxisomal oxidation [10,15,16]. Some of these events can be exacerbated by variants of genes involved in lipid metabolism. In addition, increased mitochondrial β-oxidation of free fatty acids (FFAs) may be potentially deleterious. Coenzyme A-linked FFAs are shuttled into the mitochondrial matrix through carnitine O-palmitoyltransferase 1 (CPT)1 and CPT2, but this leads to excessive amounts of acetyl-CoA entering the tricarboxylic acid cycle and of NADH entering the mitochondrial electron transport chain. The resulting increase in mitochondrial oxidative metabolism can lead to an exhaustion of superoxide dismutase (SOD)-2 and glutathioneperoxidase activity, ultimately resulting in the increased production of reactive oxygen species (ROS) and of oxidative stress [10,16]. Disruption of lipid metabolism (as well as of glucose metabolism) represents a key driver not only of MASLD progression but also of MASH-related HCC development [11]. Indeed, the interconnected metabolic abnormalities described above (IR, increased DNL and gluconeogenesis, increased hepatic delivery and synthesis of FA, impaired β-oxidation, increased oxidative stress, and persistent inflammatory responses) act synergistically to promote hepatic fat accumulation, inflammation, and fibrosis, thereby creating a pro-carcinogenic microenvironment. For example, abnormal glucose and lipid metabolism can promote HCC development by stimulating cell proliferation, inhibiting apoptosis and inducing genetic mutations [11]. An additional relevant role in MASLD progression is played by LXR/cholesterol pathways. LXRs are members of the nuclear receptor superfamily and pivotal regulators of lipid metabolism [17]. Elevated intracellular cholesterol concentrations trigger the synthesis of oxysterols, which in turn activate LXR-dependent transcriptional programs. These programs facilitate cholesterol efflux, suppress de novo synthesis and influx, and coordinate the metabolism of phospholipids and FA [18,19]. LXRs play a central, yet paradoxical, role in MASLD and MASH [16]. Patients with MASLD/MASH exhibit significantly increased hepatic expression of LXRα and its target genes, which correlated with the severity of steatosis, inflammation, and fibrosis [16]. Although LXR activation may be beneficial in reducing hepatic cholesterol levels and inflammation, it simultaneously promotes FA accumulation by increasing DNL, thereby driving and worsening liver steatosis. Studies in mice lacking LXR and fed lipid-enriched diets have reported resistance to obesity, decreased lipogenic gene expression and reduced steatosis; however, these mice still accumulate cholesterol that promotes steatohepatitis [16]. 2. The Drivers of MASLD Progression to MASH, Liver Fibrosis, Cirrhosis and HCC The subject analyzed in this section would in itself require a dedicated review, but since the present review is dedicated to the role of the OSM/OSMRβ axis, only a selection of major issues will be briefly proposed here as a general guide to the current understanding of how MASLD can progress. Interested readers can find more detailed descriptions of the issues discussed in a number of excellent and authoritative reviews [3,6,10,11,15,16]. According to the current literature, MASLD progression is a very complex process involving several mediators, cell types and mechanisms involving critical events, such as hepatocyte injury and death, chronic inflammatory response, fibrogenesis, genetic variants, lipotoxicity, oxidative stress and many others, including gut microbiome and dysbiosis. As previously mentioned, simple liver steatosis is detected in 75–80% of patients with a diagnosis of MASLD, usually in obese and/or T2D patients. Although just a subset of patients with simple steatosis may progress to MASH and advanced fibrosis, these patients remain at significant risk to develop cardiovascular diseases and extrahepatic cancers [3,10,11,15,16]. 2.1. Hepatocyte Injury and Death: A Matter of Altered Metabolism, Lipotoxicity, Oxidative Stress and Mitochondrial Dysfunction From a histopathological perspective, MASH is characterized by features of sublethal hepatocyte injury (often referred to as ballooning degeneration) [20] as well as of evidence of cell death. According to the current literature, cell death can be ascribed to different forms of regulated cell death, mainly including apoptosis, necroptosis, pyroptosis and ferroptosis, as extensively reviewed elsewhere [21,22,23,24]. Although the relative quantitative contribution of these different types of cell death to disease progression remains unclear, damage-associated molecular patterns (DAMPs) released by dead hepatocytes are undoubtedly critical to the chronic induction of inflammatory response under MASH conditions [10,15,21,22,23,24]. Hepatocyte injury and death under MASH conditions can be triggered by different stimuli, factors and conditions but with lipotoxicity, oxidative stress and mitochondrial dysfunction playing the most relevant roles [10,15,21,22,23,24]. Lipotoxicity deserves a brief mention here since it is a consequence of the previously described excess hepatic delivery of lipid substrates to as well as the associated impairment of lipid-related metabolic pathways. This particular scenario is believed to generate lipotoxic lipids that, by inducing critical events such as mitochondrial dysfunction, endoplasmic reticulum (ER) stress and oxidative stress, ultimately trigger hepatocyte injury and death and then genomic instability, persistent inflammation, and chronic activation of fibrogenesis [10,15,21,22,25]. Monounsaturated FA (particularly palmitate and stearate), ceramides, lysophosphatidyl choline, lysophosphatidic acid and diacylglycerols are the major directly cytotoxic lipids. These toxic lipids have been reported to induce apoptosis through the activation of c-Jun-N-terminal kinases (JNK) and mitochondrial death pathways, as well as through induction of ER stress and inflammasome activation [22,25]. In addition, lipotoxicity can induce the release of extracellular vesicles (EVs) from fat-laden hepatocytes, which can exert pro-inflammatory, pro-fibrogenic and pro-angiogenic effects on surrounding cells [26,27,28,29]. Cell injury can be exacerbated by free cholesterol [16,17] and its accumulation in hepatocytes, Kupffer cells (KCs) and hepatic stellate cells (HSCs), which results in oxidative stress, mitochondrial dysfunction and ATP depletion, leading to either apoptosis or necrotic-like cell death [10,22]. 2.2. Genetic Variants Apart from the mechanisms that can lead to hepatocyte injury and death, it now clear that MASLD progression to more advanced stages of the disease can occur primarily in patients carrying one or more genetic variants in genes encoding for proteins involved in lipid metabolism (patatin-like phospholipase domain containing 3 or PNPLA3, transmembrane 6 superfamily member 2 or TM6SF2, membrane bound O-acyltransferase domain-containing 7 or MBOAT7), glucose uptake (glucokinase regulator or GCKR), VLDL secretion (apolipoprotein B or APOB, microsomal triglycerides transfer protein or MTTP), mitochondrial lipid metabolism (uncoupling protein 2) or in the control of oxidative stress, inflammation and fibrogenesis (collagen-type XIII alpha 1 chain or COL13A1, EF-Hand Calcium Binding Domain 4B or EFCAB4B, Farnesyl-diphosphate farnesyltransferase 1 or FDFT1, Interferon Lambda 4 or IFNL4) [22,30,31,32]. These gene variants have been reported to be strongly associated not only with susceptibility to the development of MASLD but also with susceptibility to MASH and fibrosis (such as PNPLA3, TM6SF2, APOB, MBOAT7, IFNL4) and even to the development of HCC (PNPLA3 and APOB). This means that in each individual, the presence of these variants represents an additive and critical driver of progression in addition to the metabolic and dietary ones. Moreover, it has been proposed that MASLD itself should be considered a heritable disease on the basis of epidemiological, familial aggregation and twin studies [30,31,32]. Interested readers can find more extensive and detailed analyses of the relationships between the presence of genetic variants, the susceptibility to MASLD and disease progression in a number of authoritative reviews [31,32,33,34]. 2.3. Chronic Inflammatory Response: A Focus on the Role of Macrophages in MASLD Progression MASLD progression within the previously described scenario of dysregulated metabolism and persistent hepatocyte injury and death is driven by two essential and interconnected processes: the chronic inflammatory response and the chronic activation of repair mechanisms (i.e., liver fibrogenesis, see the next section) [10,15,24,35]. The persistent inflammatory response fuels progression and fibrogenesis and involves primarily several innate and adaptive immune cells. The application of novel single-cell multiomic technologies as well as of spatial trancriptomics, imaging mass cytometry and other advanced techniques has started to reveal several major features: (i) the hepatic landscape of innate and adaptive immune responses in either patients or murine models is significantly reshaped during steatohepatitis, a process that deeply affects disease progression and HCC development [36,37,38,39]; (ii) MASLD-associated inflammation reflects systemic changes and is sustained and/or modulated by multiple intrahepatic and extrahepatic factors, with inflammatory signals originating from adipose tissue, the gut, skeletal muscle, and bone marrow; (iii) the disease progression relies on an extremely complex network of cell-to-cell interactions among innate immunity cells such as KC, monocyte/macrophages and neutrophils recruited from peripheral blood, and dendritic cells; adaptive immune cells, including B and T lymphocytes, cluster designation (CD) 4+ and CD8+ T lymphocytes, and TH17 cells; innate lymphoid cells like NK and NKT cells, regulatory T cells (Treg); hepatic myofibroblasts and their precursor cells (mainly HSC and portal fibroblasts), as well as injured hepatocytes, activated platelets and sinusoidal endothelial cells (SECs). This very complex scenario is briefly summarized in Figure 1 [10,15,22,24,25,35,36,37,38,39]. In this section, we will primarily focus on the prominent role of macrophages, but interested readers can find more details about the role of other innate or adaptive immunity cells in MASLD progression in a number of recent and authoritative reviews [10,15,36,37,40]. The role of adaptive immunity will be revisited later in relation to the development of MASH-related HCC. In this scenario, a major role is unequivocally played by the activation of KCs, which is particularly relevant in the early phases of the disease, and by that of macrophages recruited from circulating monocytes (MoMs) becoming predominant afterwards [36,37,41]. Literature data indicate that macrophages play a dual role in the initiation and progression of MASLD and MASH. The following major issues regarding MASLD progression can be highlighted: (i) Under physiological conditions, KCs perform several functions as resident macrophages and represent a heterogeneous cell population in both the human and murine liver [41]. During the early stages of MASLD, they acquire a pro-inflammatory phenotype through the activation of pattern recognition receptors (PRRs) by DAMPs (ADP, free cholesterol, mitochondrial DNA, etc.) released by injured and fat-laden hepatocytes as well as by pathogen-associated molecular patterns (PAMPs) reaching the liver as a consequence of intestinal barrier dysfunction and microbial dysbiosis. (ii) Under conditions of persisting injury, KCs diminish in number, and the inflammatory response is then sustained by macrophages derived from infiltrated Ly6Chigh monocytes (MoMs), which replenish the KC niche and form the so-called TREM2+ lipid-associated macrophages (LAMs) [41,42]. (iii) TREM2+ LAMs form the so-called hepatic crown-like structures (hCLS), which are histopathologically identifiable structures in which macrophages accumulate around fat-laden and degenerating hepatocytes. During this early phase, TREM2+ LAMs have an effective efferocytic capacity that enables them to clear apoptotic cells and limit the detrimental accumulation of free lipids, thereby reducing the release of DAMPs and the inflammatory response. (iv) Under conditions of persistent lipotoxic injury, LAMs shed TREM2 (which is released as soluble TREM2) and progressively lose their efferocytic capacity. LAMs or TREM2+ macrophages are subsequently transformed into fully activated pro-inflammatory cells releasing IL1β, TNFα and other mediators (see Figure 2) that drive both inflammation and fibrogenesis. Before concluding this section, we would like to mention the potential role of the “liver-spleen axis” in the development of CLD, which is defined as a bidirectional interaction between the spleen and the liver through vascular, immunological and metabolic pathways [43]. The concept of the liver–spleen axis is supported by clinical observations demonstrating a close relationship between the two organs during CLD progression. Splenomegaly and hypersplenism are well-recognized manifestations of liver cirrhosis [44], whereas in MASLD patients, spleen enlargement has been reported to correlate with the severity of hepatic fat accumulation, further suggesting the existence of functional crosstalk between the liver and the spleen [45,46]. Since, to the best of our knowledge, no evidence currently directly links OSM or OSM-related pathways directly to the liver–spleen axis in MASLD, we will only briefly summarize some of the major concepts emerging from recent studies, particularly those related to inflammatory and immune mechanisms [43,47,48]. As is well known, the spleen serves as a major immunological organ, as well as a reservoir and modulator of myeloid and lymphoid cells. Recent evidence suggests that obesity and MASLD are associated with a splenic immune remodeling that may contribute to the maintenance of systemic low-grade inflammation and the amplification of hepatic inflammatory responses [43,49]. In particular, we would like to focus on the following points: (i) the liver–spleen axis has been proposed to sustain obesity-induced systemic inflammation and fatty liver disease through the enrichment and activation of myeloid-derived suppressor cells (MDSCs) and NK/NKT cell populations, which subsequently modulate hepatic immune responses [50]; (ii) experimental evidence suggests that CD11b+ CD43hi Ly6Clo splenocyte-derived macrophages may contribute to the expansion of the hepatic macrophage compartment during MASLD progression to promote chronic inflammation and fibrogenesis [51]; (iii) a very recent study, which confirmed the presence of enlarged spleens in patients with MASLD, identified induced TRNP1hi CD8+ T cells in the spleens of MASLD/MASH mouse models and patients. These cells exhibited pro-fibrogenic properties through the secretion of INSR-α that ultimately contribute to activating HSC [52]. Overall, although the potential interaction between the OSM/OSMRβ axis and the liver–spleen axis has not yet been investigated, these studies suggest that the spleen may act as an active contributor to liver disease progression, an issue that deserves further investigation. Interested readers may find more information about the role of the spleen–liver axis in a recently published review [43]. 2.4. Fibrogenesis Liver fibrogenesis, the biological process leading to fibrosis (i.e., the excessive deposition of extracellular matrix or ECM), is mainly sustained by a heterogeneous population of hepatic α-smooth muscle actin-positive (αSMA) cells defined as myofibroblasts (MFs). MFs originate from different precursor cells of mesenchymal origin through a process defined as of activation/transdifferentiation [10,53,54,55,56]. Hepatic MFs, in addition to being activated by a plethora of mediators (growth factors, cytokines, chemokines, ROS, adipokines, proangiogenic factors, released by KC and macrophages, damaged hepatocytes, SEC, platelets, cholangiocytes, NK cells, NKT cells and other cells of the adaptive immunity (i.e., as in any form of CLD)), can also respond to metabolic signals as well as signals related to gut dysbiosis or delivered from adipose tissue [10,53,54,55,56]. The following major issues regarding the role of liver MFs in the MASLD/MASH (see also Figure 1) can be summarized as follows [10,53,54,55]: (i) In progressive MASLD, MFs originate mainly through the activation/transdifferentiation of quiescent HSC and only marginally from other precursors like portal fibroblasts. (ii) As described for other CLD of different etiologies, MFs exhibit classical phenotypic responses, including (a) active proliferation in response mainly to platelet-derived growth factor (PDGF), transforming growth factor α (TGFα), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF) and leptin; (b) excess deposition of ECM as induced by transforming growth factor β1 (TGFβ1), bFGF, CTGF); (c) reprogramming of ECM remodeling due to the overexpression of tissue inhibitors of metalloproteases (TIMP) and of matrix metalloproteases (MMPs) that are unable to efficiently remove fibrillar collagen; (d) a pro-angiogenic role responding to hypoxic conditions through the release of vascular endothelial growth factor (VEGF), Angiopoietin-1 and -2, Hedgehog ligands; (e) a pro-inflammatory role involving the release of CC chemokine ligand-2 or -21 (CCL2, CCL21), interleukin 1β (IL1β), responses to several inflammatory mediators and the ability to migrate (as induced mainly by PDGF, CCL2, VEGF, Angiotensin I). (iii) The removal of the etiological cause of CLD is the predominant event that allows fibrosis to arrest or even regress. Fibrosis regression is accompanied by a number of relevant changes, including the decreased synthesis of pro-inflammatory and pro-fibrogenic mediators, the decrease in the synthesis of ECM components and the predominance of MMP activity over TIMP activity. When this ideal condition occurs, approximately 50% of HSC-derived MFs can undergo apoptosis, an event reported to be induced by NKT and pro-resolution macrophages. HSC-derived MFs that escape apoptosis can either become inactivated or dedifferentiated or become senescent and subsequently undergo apoptosis, possibly with the active contribution of activated NK cells. It should be noted that recent data obtained using single-cell transcriptomics have revealed that HSCs should be considered a more heterogeneous cell population than previously believed [57]. In addition, HSCs have been proposed to contribute to the regulation of carbohydrate, mitochondrial and lipid homeostasis, suggesting that in order to undergo activation/transdifferentiation into MFs, HSCs need to rapidly adapt metabolically [56]. Accordingly, these adaptations should include the reprogramming of carbon metabolism and enhanced mitochondrial number and activity, as well as ER stress, and the release of FFA through the autophagy-dependent hydrolysis of retinyl esters stored in cytoplasmic droplets [56]. The available literature clearly indicates that HSCs as well as HSC-derived MFs during the course of any CLD, including progressive MASLD, are able to establish extensive crosstalk with practically all other cell types involved in disease progression. This means that HSCs and MFs are cells capable of sensing a plethora of signals and mediators and to respond to them by releasing, in an autocrine/paracrine manner, several mediators, as unequivocally shown for TGFβ1, PDGF, VEGF, CCL2 and other mediators [10,53,54,55,56,58]. This scenario is summarized in Figure 1. It should be emphasized that all these cell-to-cell interactions are critical not only for MASLD progression but also for HCC development, with several ligand–receptor axes indicated as putative biomarkers of progression or suitable molecular targets for novel therapeutic strategies [3,6,7,11,15,35,37,40]. In the next sections of this review, we will focus on the emerging role of the OSM/OSMRβ axis in CLD progression and HCC development, with a focus on MASLD and MASH. 3. Oncostatin M: Introducing a Peculiar and Enigmatic Cytokine 3.1. Oncostatin M: Introductory Remarks Oncostatin M (OSM) is a 22–26 kDa pleiotropic and multifunctional cytokine (depending on the species) belonging to the interleukin-6 (IL6) family of cytokines [59] that was originally identified as a protein produced by U937 cells (a cell line derived from human histiocytic lymphoma) [60]. The IL6 cytokine family also includes leukemia inhibitory factor (LIF), a number of interleukins (IL11, IL27, IL30 and IL31) cardiotrophin-1, ciliary neurotrophic factor and cardiotrophin-like cytokine factor 1 [61,62,63,64]. In particular, OSM shares a high level of homology (structural, functional and genetic) with LIF [59,62], possibly due to an ancestral event of gene duplication [65]. The name “Oncostatin M” reflects the initial finding that identified this cytokine as cytostatic toward melanoma cells [60]. However, literature data indicate that OSM can modulate several processes, under both physiological or pathological conditions, including cell proliferation, extracellular matrix remodeling, hematopoiesis, differentiation, inflammatory responses, angiogenesis and the acquisition of cancer stem cell markers and of a metastatic phenotype [61,62,63,64]. OSM is produced and released by different types of cells, including cells of the innate (mainly monocytes/macrophages, dendritic cells and neutrophils) and adaptive (T lymphocytes) immune system as well as hematopoietic cells, mesenchymal cells [61,62,63,64,66] and even cancer cells, as recently shown in liver cancer cells from MASH-related HCC [67]. 3.2. OSM: Transcription, Biosynthesis and Secretion Over the past two decades, different laboratories have cloned the human, murine and rat OSM orthologues, as reviewed in ref. [66]. Interestingly, the exon–intron structure of the OSM-encoding gene has been reported to be identical among these species, consisting of three exons separated by two introns. Moreover, the gene is always located in direct proximity to the gene encoding LIF, suggesting that both genes may have originated from a gene duplication event [68,69]. The promoters of the human (hOSM) and murine (mOSM) genes have been characterized, and available evidence indicates that they are controlled by CCAAT-enhancer-binding proteins (C/EBP) and GC-rich elements that regulate basal activity. However, signal transducer and activator of transcription (STAT)5 responsive elements are believed to be critical for stimuli-induced OSM transcription, whereas transcriptional silencer(s) (located between nt 194 and 109) in the human OSM promoter appear to ensure cell-specific control of gene expression [70,71]. For example, in hematopoietic cells, OSM transcription is strongly up-regulated by cytokines operating through STAT5, like IL2, IL6, erythropoietin and granulocyte–monocyte colony stimulating factor. OSM transcription has been reported to also be up-regulated by prostaglandin E2 via the cAMP signaling pathway [72,73]. Of interest, OSM is regarded as an amplifier of cytokine production/release [66], and both the human and murine OSM mRNAs contain several AU-rich sequences known to contribute to increased mRNA stability for several cytokines, including IL6 [74]. Following translation, full-length OSM proteins have been reported to contain from 239 to 263 amino acids with a 3D structure folded into a long-chain four-helix bundle with an up-up-down-down topology closely similar to those of other IL6 family cytokines [66]. OSM proteins are then post-translationally modified by N-glycosylation that seems to differ depending on the specific cell type [75]. Regarding hOSM (with the corresponding murine and rat data being at present less clear), following the post-translational cleavage of C-terminal prodomain and the N-terminal signal peptide, the protein results in 195 amino acids and 22 kDa, which has been reported to elicit the highest biological activity, although the 24 kDa isoform also appears to exhibit similar activity in competition assays [75]. Both protein forms can bind to the receptor complex (see the next section) with high affinity but exhibit different growth inhibitory activities: the 24 kDa isoform is 5- to 60-fold less active in growth inhibition assays using A375 melanoma cells [75]. Once secreted, OSM has been reported to bind, in its bioactive form, to various ECM components including different types of collagen (I, III, IV, VI and XI) as well as to laminin and fibronectin [76,77]. This is a unique property of OSM since other cytokines belonging to the IL6 family do not bind to ECM components. It has been proposed that OSM, within an inflammatory microenvironment, may act as a strong inducer of ECM deposition [78,79]. 3.3. OSM, Related Receptors and OSM-Dependent Signaling Pathways OSM acts by binding to two different heterodimeric receptors, which have in common the glycoprotein 130 (gp130), a membrane receptor protein shared by all members of the IL6 family of cytokines. OSM has been reported to first interact with the extracellular cytokine-binding domain of gp130, subsequently recruiting either the LIF receptor β (LIFRβ) to form the OSM type I receptor or to the OSMRβ to form the OSM type II receptor. The two heterodimeric receptors are differentially engaged in humans and mice: human OSM can bind to either gp130/OSMRβ or gp130/LIFRβ, whereas murine OSM binds only to the type II receptor [80,81,82,83]. Interestingly, the OSMRβ/LIFRβ ratio and the differential expression of these receptors in various cell type have been proposed as the mechanism by which OSM and LIF may exert common biological effects on particular tissues but distinct and relatively unique in other tissues [81]. It should be noted that OSMRβ is believed to mediate most OSM effects [61] by mainly activating the Janus kinase (JAK)/STAT) pathway [61], as well as the Ras–mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinases (ERK) 1/2 and p38 pathways [82,83]. Regarding activation of the JAK/STAT pathway, the interaction between OSM and gp130 is known to initially induce receptor heterodimerization and then to the recruitment and activation of JAK1, JAK2 and tyrosine kinase 2 (TYK2). In particular, the C-terminal domains of both OSM receptor type I and II contain tyrosine motifs, which, once phosphorylated by JAK1 and JAK2, act as docking sites for STAT1 and STAT3. OSM has been reported to activate STAT5 and STAT6 [61,62,81]. In addition to activating the JAK/STAT pathways, OSM can also recruit the adaptor Src homology and collagen (Shc) protein to the conserved Tyr861 residue of the OSMRβ. This can lead to the activation of a number of downstream kinases such as ERK1/2, p38, or JNKs [61,66,81,83], as well as, in some cells, the phosphatidyl inositol 3-kinase (PI3K)/Akt pathway [84] and the protein kinase C δ [85]. Finally, it has been reported that OSM can also negatively modulate mitogen-activated protein MAPK signaling cascades through the recruitment of the tyrosine phosphatase SHP-2 (specifically to the Tyr759 and Tyr974 residues of the type I receptor), the recruitment of suppressors of cytokine signaling (SOCS, in particular SOCS3) on Tyr759, or through the direct action of JAK1/2 [61,66,81]. 4. Biological Activities of Oncostatin M: A Complex Scenario As mentioned in the previous section, OSM should be regarded as a pleiotropic and somewhat enigmatic cytokine that is produced and released by several cell types. OSM has been reported to induce or modulate various biological processes, particularly under pathological conditions. According to the current literature on pathological conditions, OSM can affect inflammatory responses, cell proliferation, angiogenesis, epithelial to mesenchymal transition (EMT), invasiveness, metastasis and the behavior of cancer stem cells (CSC) [61,62,63,64]. More recently, OSM has been reported to have a role in reshaping the tumor immune microenvironment [86]. 4.1. OSM in Inflammatory Diseases OSM is known to play a major role in inflammation, and it has been reported to be involved in both the acute-phase response and chronic inflammatory conditions, which may eventually result in tissue or organ fibrosis and cancer [61,62,63,64,87,88]. As already mentioned, OSM can be synthesized and released by several immune cell types in response to a variety of soluble mediators. OSM can exert either pro-inflammatory or anti-inflammatory effects according to the cellular context and the intracellular signaling elicited. OSM can act as a pro-inflammatory cytokine by stimulating both receptors (predominantly OSMRβ or type II receptor) on target cells, thereby inducing the release of several cytokines and chemokines (particularly CCL2, CCL5, CCL20 and CXC chemokine ligand [CXCL] 3), with the latter contributing to the recruitment of neutrophils and monocytes [61,62,63,64,87,88]. Interestingly, the anti-inflammatory action of OSM is mediated primarily through the type I receptor (LIFR). Moreover, under chronic inflammatory conditions, OSM and OSMRβ are often overexpressed, with OSM generally regarded as a cytokine capable of sustaining inflammation and to promoting fibrosis. In particular, the role of OSM has been investigated in several chronic inflammatory diseases, including lung diseases, inflammatory bowel disease, cardiovascular diseases, skin diseases, arthritis, COVID-19 and many other conditions, as reviewed in ref. [64]. It should be noted at the outset that OSM has been reported to exert either positive or negative effects on different diseases, with strategies designed to inhibit OSM-related signaling being beneficial in some diseases but detrimental in others [64]. Here, we will briefly focus only on a few relevant examples of diseases in which OSM and OSM-related signaling have been proposed to be relevant. Interested readers can refer to a more comprehensive review [64]. Regarding lung diseases, for example, OSM has been reported to be up-regulated and to play a critical role in patients affected by pulmonary fibrosis and asthma. In both diseases, as has also been commonly observed in diseases affecting other tissues, OSM up-regulation paralleled the extent of lung chronic inflammation, the accumulation of profibrotic macrophages and the excessive deposition (particularly in lung fibrosis) of ECM components, suggesting that OSM and related pathways may sustain the development and progression of these lung diseases [89,90,91]. Another interesting example is represented by inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, in which OSM and OSMR are overexpressed in many IBD lesions [92]. Moreover, a retrospective study showed that patients with increased levels of OSM and who were treated with anti-TNFα therapies had, one year later, a lower chance of remaining in remission [93]. Similarly, IBD patients having high levels of OSM and OSMR expression before infliximab therapy showed a significantly lower response to treatment [94]. In the latter study, the use of OSM-knockout mice in a murine IBD experimental model resulted in a highly significant decrease in disease severity, confirming that OSM signaling not only represents a key feature of IBD pathogenesis but can also negatively interfere with anti-TNFα therapies [95]. Along these lines, it is interesting to note that JAK/STAT inhibitors like tofacinib (inhibitor of JAK1 and JAK3) and filgotinib (selective inhibitor of JAK1) are currently being evaluated in clinical trials for IBD, as reviewed in ref. [64]. A closely related scenario has emerged from studies on rheumatoid arthritis, in which OSM and IL1β once again play critical roles in disease pathogenesis and progression [64]. In vitro studies have shown that OSM increases the deleterious effects of TNFα through the activation of STAT3 signaling and that tofacinib exerts significant positive effects [94,95]. In an in vivo study using a murine model of arthritis, the administration of anti-OSM antibodies resulted in a significant improvement in the experimental disease [96], leading to the design of dedicated clinical trials employing anti-OSM therapeutics (GSK315234 and GSK2330811) [64]. Unlike its role in IBD and arthritis, the role of OSM in cardiovascular disease remains controversial. Persistent OSM-dependent STAT3 activation has been reported by some studies to exert detrimental effects on arterial vessels and to promote atherogenesis [97,98]. However, another study indicated that chronic OSM administration in mice reduced atherosclerosis development; moreover, patients with higher serum levels of OSM showed improved survival to coronary heart disease [99]. Experimental in vivo studies have also indicated that OSM increases cardiac function following myocardial infarction [100,101]. 4.2. OSM in Cancer Biology The multifaceted role of OSM is emphasized by studies investigating its involvement in cancer biology. There is general agreement that OSM (and/or OSM/OSMRβ axis) plays a predominantly deleterious role in cancers affecting several different tissues and organs. The available literature on solid human cancers (see, for a detailed review, ref. [64]) indicates that the involvement of OSM is sometimes particularly relevant in specific cancer types, including, for example, ductal carcinoma of the breast, ductal adenocarcinoma of the prostate and of pancreas, adenocarcinoma of the lung and of colon, squamous cell carcinoma of the cervix and of the skin. With regard to brain cancers, OSM has been implicated in practically all major types (i.e., astrocytoma, astroglioma, glioblastoma, medullo blastoma, etc). A detailed analysis of the involvement of OSM in human cancer is beyond the scope of this review, and we will, therefore, highlight only some of the most common findings reported in refs. [62,63,64]: (i) in most human solid tumors, OSM is usually overexpressed, particularly in the tumor mass, and the expression has been reported for some tumors to correlate with poor prognosis; (ii) in several tumors, it has been outlined that OSM and the OSM/OSMRβ axis (often through involvement of STAT3) are strictly related to increased epithelial-to-mesenchymal transition (EMT) and increased invasiveness and metastasis; (iii) another common finding is that activation of the OSM/OSMRβ axis results in increased pathological angiogenesis, with a direct correlation between OSM and VEGF expression; (iv) in some cancer types, although not all, OSM is able to stimulate proliferation of cancer cells; (v) OSM is emerging as a cytokine potentially capable of reshaping the tumor immune microenvironment (TIME). A few isolated examples of beneficial effects exerted by OSM have also been reported in specific cancers such as chondrosarcoma, in which OSM apparently induced cell cycle arrest and enhanced apoptosis in cancer cell lines [64,102] and melanoma, in which OSM has been reported to inhibit cancer cell proliferation [64,103]. 5. The Role of OSM in Chronic Liver Diseases and in MASLD/MASH According to the aforementioned literature, OSM and the related OSMRβ/JAK/STAT signaling axis have been reported to regulate critical biological processes under normal and pathological conditions, including cell proliferation, extracellular matrix remodeling, hematopoiesis, differentiation, inflammatory responses, angiogenesis, acquisition of cancer stem cell markers and of a metastatic phenotype. In the liver, these processes also include hepatic development and regeneration [59,61,63,64,87,104]. All these critical processes are known to be deeply involved in the progression of CLDs of different etiologies toward more advanced pathological stages, including cirrhosis and liver failure as well as HCC development [41,53,54,56,57]. In the following sections, we will analyze literature data on the roles of OSM in CLDs, with a focus on progressive MASLD and MASH-related HCC. For interested readers, we also note, although not reviewed in this study, that OSM is emerging as a mediator involved in the development of intrahepatic cholangiocarcinoma [63]. 5.1. OSM in Chronic Liver Diseases: A Pro-Inflammatory and Pro-Fibrogenic Mediator One of the earliest in vivo studies involving OSM in CLD was an immunohistochemistry study performed on a limited number of human specimens obtained from either cirrhotic livers (n = 6) and donor livers (n = 4) not used for liver transplantation [105]. This preliminary morphological study concluded that OSM was mainly expressed by CD68-positive cells, most likely Kupffer cells. Its expression was low and variable in control livers but significantly higher in cirrhotic livers. The authors of this pioneering study also suggested that the expression of OSMRβ, which was very low in normal hepatocytes, was apparently unchanged in cirrhotic livers, with LIFRβ being weakly expressed in normal livers but more intensely expressed in cholangiocytes of reactive biliary ductules in cirrhotic livers [105]. Although the authors analyzed only a few cirrhotic livers of unreported etiology, these data supported previous studies from the same research group indicating that OSM was able to up-regulate the expression of collagen type I and of TIMP1 by liver MFs derived from activated HSCs [106]. To our knowledge, these two studies were the first to identify OSM as a putative profibrogenic mediator. In those years, another study reported that knockout (ko) mice for OSMRβ treated with the hepatotoxin carbon tetrachloride (CCl4) or subjected to partial hepatectomy showed impaired liver regeneration compared with control mice. Moreover, reduced expression of TIMP1 and TIMP2 was also reported in these KO mice, thus suggesting that OSM is a mediator involved in hepatocyte proliferation and tissue remodeling [107]. Along these lines, one study showed that OSM, in addition to being expressed by KC, was also expressed in oval cells in the rat model of 2-acetylaminofluorene/partial hepatectomy and regeneration. Moreover, the OSM receptor was found mainly on oval cells, suggesting that the OSM/OSMR system may be critical for promoting oval cell differentiation into hepatocytes [108]. In addition, in a rat experimental model of liver injury induced by repeated injections of dimethylnitrosamine, it was shown that OSM operated as a key mediator for hepatocyte proliferation and survival [109]. A subsequent study provided the first evidence suggesting that OSM may contribute to liver angiogenesis, a critical process in both physiological and pathological conditions, by up-regulating the transcription and synthesis of hypoxia-inducible factor (HI) 1α in HepG2 cells as well as in the PH5CH8 human hepatocyte through OSM-dependent JAK/STAT3 and ERK1/2 signaling pathways. Accordingly, this HIF1α up-regulation also resulted in increased expression of HIF1-downstream genes encoding for VEGF and plasminogen activator inhibitor 1 [110]. Interest in the role of OSM in CLD was renewed by an in vitro study reporting that the administration of OSM to cultured human HepG2 cells resulted in a strong up-regulation of GP73 [111], a glycoprotein proposed as a biomarker of cirrhosis and HCC [112,113]. Interestingly, the response of HepG2 cells to OSM was far greater than their response to IL6. The involvement of OSM in CLD progression was proposed relatively early [92,93,94], based in part on preliminary data indicating that OSM was able to up-regulate collagen type I and TIMP1 expression in activated HSC or liver MF [106,114] as well as evidence that hepatocyte proliferation and tissue remodeling were impaired following persistent liver injury in mice with genetic deletion of the OSM receptor [107]. However, the first convincing study that mechanistically correlated OSM to liver fibrogenesis was not published until 2017 [115]. In this study, OSM was proposed to act as a pro-fibrogenic mediator by regulating the activation of macrophages during chronic liver injury. The authors of this study employed mice with genetic deletion of OSM that were then chronically treated (12 weeks) with the hepatotoxin thioacetamide (TAA). OSM deletion resulted in a significant reduction in liver fibrosis and in the expression of both collagen 1a1 and TIMP1 compared with wild-type animals, without affecting parameters of hepatocyte injury. Moreover, the exposure of co-cultures of HSC and liver macrophages to recombinant OSM resulted in significantly increased expression of critical pro-fibrogenic mediators like PDGF and TGFβ together with the up-regulation of TIMP1 by HSCs. In addition, continuous OSM expression, obtained by employing the procedure of hydrodynamic tail vein injection of OSM, was sufficient to induce liver fibrosis. Finally, by overexpressing OSM and performing fluorescence-activated cell sorting, these authors proposed that macrophages recruited from peripheral blood were responsible for OSM-dependent pro-fibrogenic activation of HSC [115]. Although this study was partly performed using the TAA model of chronic liver injury that is not fully representative of the human condition, it was the first to unequivocally demonstrate the pro-fibrogenic action of OSM [115]. A study from our laboratory provided further support for the concept that OSM can operate as a pro-fibrogenic mediator by showing that human recombinant OSM (hrOSM) was able to stimulate the oriented migration (i.e., chemotaxis) of human MF-like LX2 cells, originally derived from activated HSC [116]. In particular, OSM was reported to stimulate MF migration by eliciting an increase in intracellular ROS and through activation of STA1/STAT3 (with activation of Ras/Erk, JNK1/2 and PI3/Akt signaling pathways also detected in LX2 cells). In addition, OSM also induced the recruitment and stabilization of HIF1α, confirming what was previously described by other authors [110]. This finding is relevant since, in the same study, evidence was provided that OSM-dependent migration relied on a biphasic mechanism requiring the early intracellular generation of ROS and the subsequent HIF1α-dependent expression and release of VEGF. VEGF, in turn, contributes to oriented migration of LX2 cells stimulated by OSM. hrOSM was also able to increase the transcription of pro-inflammatory mediators like the chemokine CCL2 and the cytokines IL6 and TNFα in LX2 cells [116]. OSM was also proposed in a clinical study to be an essential component of an immune gene signature capable of predicting advanced fibrosis in CLD of mixed etiologies. The study analyzed snap-frozen liver tissues from patients at different stages of fibrosis. The other components of the immune signature were all factors related to chronic injury and inflammation, including, in addition to OSM, VEGFA, Chitinase 1, Fc fragment of IgE–high-affinity I receptor for gamma polypeptide and zeta chain of T-cell receptor-associated protein kinase 70. This signature was reported to discriminate between patients with a low grade of fibrosis (i.e., F1 andF2) from those with more advanced stages of fibrosis (F3 and F4). Interestingly, the signature was reported to be independent on pathological and clinical features, with OSM and other factors reported to decrease in more advanced stages [117]. In a more recent study using a rat model of liver fibrosis induced by chronic administration of CCl4, OSM was found to be the main up-regulated cytokine (together with IL1β). Moreover, OSM was reported to be produced and released by KCs, macrophages and endothelial cells. Interestingly, according to this study, the target cells were hepatocytes, endothelial cells and HSCs, all of which expressed the necessary receptors [118]. A final point concerning liver fibrogenesis relates to a recent study investigating early events in a murine model of alcohol-associated liver disease (ALD), which revealed an interesting relationship between OSM and Yes-associated protein (YAP) [119]. YAP is a transcriptional coactivator and downstream effector of the Hippo signaling pathway, which has been implicated by a number of studies in the pathogenesis of various liver diseases [120,121]. YAP−/− mice, mice injected with an adeno-associated virus 9-delivered saCas9/sgYAP system or YAPΔHep mice were fed the Gao-binge diet to mimic early ALD events. YAP deficiency was found to exacerbate early features of ALD, including steatosis and inflammatory response, whereas overexpression of YAP in hepatocytes significantly reversed these aspects. In particular, hepatocellular YAP was reported to be a negative regulator of OSM/STAT3-dependent up-regulation of CD36 [119], a well-known, critical membrane multifunctional protein that regulates the uptake of fatty acids in several cells, including hepatocytes, that play a key role in lipid metabolism, inflammation and immune response. 5.2. OSM in the Progression of MASLD/MASH Studies investigating the involvement of OSM and related signaling pathways in MASLD/MASH (or in NAFLD/NASH, as for the previous disease nomenclature) are surprisingly few and have yielded somewhat contradictory results. Given the current definition of MASLD as a spectrum of conditions encompassing steatosis, steatohepatitis with or without fibrosis, fibrosis and ultimately cirrhosis, the limited data currently available in the literature can be summarized as follows. To our knowledge, one single study has analyzed OSM serum levels and the liver expression of OSM in MASLD/MASH patients stratified according to progression of the disease [67]. OSM was reported to be almost undetectable in patients with either a diagnosis of simple steatosis or of steatohepatitis. However, OSM serum levels were significantly increased in cirrhotic patients and were dramatically raised in patients with MASH-related HCC (see below), suggesting that the relevance of OSM might be related to the progression of the disease rather than the development of fatty liver and/or the early stages of MASH [67]. Along these lines, the first report examining OSM in MASLD/MASH was published almost fifteen years ago in order to investigate the contribution of this cytokine released by KCs to hepatic insulin resistance and steatosis. This experimental study, conducted both in vitro and using two different dietary protocols to induce MASLD/MASH, proposed that prostaglandin E2 (PGE2) is produced by activated KC attenuated insulin-dependent glucose utilization by interrupting the intracellular signaling cascade downstream of the insulin receptor in hepatocytes as well as by affecting insulin resistance by modulating cytokine production in non-parenchymal cells. The authors of this study showed that OSM produced by KCs exposed to PGE2 attenuated insulin-dependent Akt activation and glucokinase induction in hepatocytes through the induction of SOCS3. In addition, OSM inhibited the expression of key enzymes involved in hepatic lipid metabolism, suggesting that OSM may contribute to both the rise in IR and the development of steatosis and then possibly MASH [73]. A few years later, another study analyzed the role of OSM signaling in obesity and related metabolic disorders. The authors used mice genetically manipulated in order to carry global deletion of the OSMRβ gene (OSMRβ−/− mice) and fed these mice on a high-fat diet (HFD). This study showed that OSMRβ−/− mice, when compared to WT littermates, exhibited a severe increase in body weight and food intake as well as an increase in peripheral adipose tissue inflammation, insulin resistance and liver steatosis [122]. This finding was unexpected since several studies on chronic inflammatory diseases had shown that OSM inhibition was effective in preventing or attenuating disease progression [59,63,64]. In particular, OSMRβ−/− mice exhibited increased expression of liver genes related to de novo lipogenesis. A major limitation of this study was that authors used mice carrying a global deletion of OSMRβ gene, resulting in the loss of its expression from all involved cells, including cells of innate (mainly monocytes/macrophages, dendritic cells and neutrophils) and adaptive (T lymphocytes) immunity as well as hematopoietic cells, mesenchymal cells as well as hepatocytes [61,62,63,64,66,67]. A more appropriate approach was reported in a study that, in addition to mice carrying global deletion of the receptor, also examined mice lacking hepatocellular OSMRβ fed on an HFD. In these mice, the dietary protocol exacerbated IR, hepatic steatosis and inflammation, effects that were markedly attenuated by the hepatocyte-specific overexpression of OSMRβ [123]. Overall, the results of these two studies should be interpreted with caution, bearing in mind that the HFD protocol is useful for reproducing steatosis but, in our experience, induces only modest inflammation and very little or negligible fibrosis. The murine HFD protocol can then, therefore, reliably reproduce just the early stage of the disease. Moreover, it should be noted these two studies did not analyze either serum or tissue levels of OSM in wild-type and genetically manipulated mice [122,123]. This is relevant since dietary protocols leading to significant inflammation and fibrosis, like high-fat/high-fructose diets or choline-deficient L-amino acid-defined (CDAA) diets, significantly up-regulated the hepatic expression of both OSM and OSMRβ at a relatively late stage, in parallel with increased collagen deposition and recruitment/activation of MFs derived from HSCs [116]. This scenario is more consistent with that described above in MASLD patients stratified by disease progression [67]. More recently, OSM has been reported to be a potential mediator of the protective effects exerted by macrophage-derived osteopontin (OPN) against the development of MASH [124]. OPN (the product of secreted phosphoprotein 1 or SPP1 gene) is a mediator whose expression correlates with TG accumulation in MASLD patients [125] and proposed as a putative profibrogenic mediator (reviewed in ref. [126]). In this study, macrophage OPN/SPP1 expression increased during MASH progression in humans and in mice fed on a very potent dietary protocol (high-fat/high-fructose/high-cholesterol diet), although its expression was also up-regulated in murine hepatocytes. This elegant and complex study, which used properly designed genetically modified mice, shows that a specific cluster of macrophages (i.e., of five identified), referred to as SPP1high, is formed by cells having maximal expression of OPN, which are also expressing TREM2 and CD9 antigens. This subset of macrophages did not exhibit pro-inflammatory or profibrogenic profiles but instead displayed a metabolic one. According to the study, these macrophages were responsible for MASH protection, which, in turn, was mediated by up-regulation of OSM. OSM acted on hepatocytes through STAT3 signaling, resulting in increased arginase expression. There are some comments that should be taken in mind: (i) the conclusions were mainly based on the use of genetically modified mice in which the SPP1 gene was either overexpressed (i.e., using SPP1 knockin mice) or deleted in myeloid cells; (ii) as suggested by the authors in their discussion, the SPP1high TREM2 and CD9-positive macrophages may behave differently during different stages of the disease; (iii) the findings of this group [124] may be consistent with the current view that TREM2 CD9-positive cells (previously defined as LAM or scar-associated macrophages) should be interpreted as cells that, in the early stages of MASH, may act as protective cells (i.e., by aggregating and surrounding lipid-laden hepatocytes to form hepatic crown-like structures, displaying efferocytic capacity and then containing local injury and inflammation). However, under conditions of prolonged lipotoxic injury, these cells acquire a more pro-inflammatory and profibrogenic phenotype (i.e., following shedding of TREM2 and losing efferocytic capacity) [41]. 5.3. OSM and HCC: Experimental and Clinical Data Not Directly Referring to MASLD/MASH As mentioned in the previous section, OSM is currently believed to be a pro-carcinogenic cytokine, as observed in several human solid tumors (see Section 4.2), a view that progressively replaced the initial idea of OSM as a cytokine capable of inhibiting proliferation, which was essentially based on in vitro studies in different cancer cell lines (reviewed in refs. [61,62,63,64]). The available literature addressing OSM and HCC is relatively limited, and only recently have OSM and its related signaling axis been investigated in human patients and in mechanistic experimental models. Interestingly, for several years, studies have investigated OSM-related effects, some of which are potentially related to a role in liver cancer, primarily by performing in vitro studies employing the widely used HepG2 human cell line. This cell line is an immortalized line of human liver cancer cells originally isolated from a liver biopsy of a 15-year-old boy with a well-differentiated hepatoblastoma, or other hepatoma cells. To our knowledge, the first study published on OSM and HepG2 cells dates back to 1991, when a biochemical article proposed that OSM was able to strongly increase the uptake of low-density lipoproteins (LDLs) through a tyrosine kinase-related mechanism, resulting in increased transcription of the LDL receptor and its increased presence on the plasma membrane [127]. These findings, which were confirmed by subsequent studies [128,129], were initially overlooked, although they conveyed a relevant message: a cytokine secreted by macrophages had effects on hepatocyte lipoprotein and cholesterol metabolism, indicating a possible connection between the immune system and cholesterol homeostasis while also demonstrating that HepG2 (i.e., liver cancer cells) expressed the receptors for OSM. The relevance of this finding is now clear since, as mentioned before and briefly discussed again below, changes in fatty acid metabolism and cholesterol pathways are particularly relevant in the pathogenesis of MASLD/MASH and MASH-related HCCs and, more generally, for liver carcinogenesis [6,10,11,12,13]. Other in vitro studies using HepG2 cells revealed a role for OSM in the regulation of the synthesis of hepatic acute-phase proteins related to coagulation, such as, for example, fibrinogen [130] and secreted phospholipase A2 [131]. They also identified a role for OSM in the up-regulation of conventional as well as soluble IL6 receptor. The latter protein lacks the transmembrane domain and has been suggested to be a potent immunomodulator of IL6 biologic activity, but once again, this finding was somewhat neglected for its putative relation to liver cancer progression [132]. In our view, the most relevant in vitro study indicated that, unlike normal hepatocytes, which express both OSM-related receptors, human hepatoma cells were characterized by a reduced expression of LIFR and reduced responsiveness to LIF. This was ascribed to epigenetic changes in hepatoma cells, resulting from the methylation-dependent inactivation of the LIFR gene. Reduced responsiveness to LIF by hepatoma cells was remarkably similar to that observed for other cancer cell lines like colon HCT8 cells, breast MCF7 cells and lung carcinoma cells [133]. If we limit the observation to hepatoma cells, the message was that liver cancer cells do not respond or minimally respond to LIF but maintain the capacity to respond to OSM through OSMRβ, suggesting that OSM can act directly on liver cancer cells. Data more directly related to HCC were published later in an attempt to clarify the role of OSM in mediating acute-phase protein (APP) gene activation [134]. By employing mice KO for amphiregulin (AR), a ligand for epidermal growth factor receptor (EGFR) and related wild-type mice, the authors of this study found that APP genes were overexpressed in the livers of AR KO mice during inflammation and hepatocyte proliferation. Moreover, for AR-null hepatocytes in culture and human HCC cells after AR knockdown, APP gene expression is enhanced, suggesting that AR counteracts OSM-triggered STAT3 signaling in hepatocytes and attenuates APP gene transcription, supporting the relevance of epithelial growth factor receptor (EGFR)-mediated signaling in the modulation of cytokine-activated pathways. This is potentially relevant because AR, which is not expressed in the normal liver, is up-regulated during chronic liver injury and, particularly, in human HCC tissues and cell lines, where it acts as a mitogenic and antiapoptotic growth factor for HCC cells [135]. A particularly interesting study investigated OSM in relation to liver cancer stem cells (CSCs) [136] based on the evidence that IL6-related cytokines can induce the differentiation of hepatoblasts into hepatocytes [137]. In this study, OSM receptor expression was found in the majority of epithelial cell adhesion molecule (EpCAM)-positive HCC cells with stem/progenitor cell features. Interestingly, OSM induced differentiation of these cells into hepatocytes through STAT3 signaling. These EpCAM-positive cells treated with OSM showed increased cell proliferation and an expansion of the EpCAM-negative non-CSC population. It was not until 2012 that OSM levels were reported to be 6–7-fold higher in sera of cirrhotic patients (carrying or not HCC) than in those of healthy controls. In cirrhotic patients, serum levels of OSM were significantly associated with GP73 levels; GP73 is a Golgi phosphoprotein protein considered at the time a putative biomarker for HCC [111]. To our knowledge, this study was indeed the first to report a very significant increase in serum OSM in cirrhotic patients (carrying or not HCC). Unfortunately, in this study, no information was provided regarding the specific etiology of cirrhosis [111]. In another study using different liver cancer cell lines (HepG2, Hep3B and Huh7 cells), OSM and IL6 were found to inhibit IL27-induced IFNγ-like, STAT1-dependent transcriptional response through a SOCS3-mediated mechanism [138]. The relevance of this study relies in the fact that IL27 is up-regulated in patients with HCC compared to healthy controls or patients with hepatitis and/or liver cirrhosis [139,140]. It should be mentioned that HCC is an immunosensitive tumor and that TH1 cytokine detection in patients is usually associated with a good prognosis, with type I interferons, IFNγ and IL12 being crucial for immune-mediated rejection of HCC [141]. Accordingly, IL27 has been proposed as a putative antitumor molecule with an effect mediated by increased antigen presentation but just combining the treatment with blocking antibodies against PD-L1 or/and IL6-type cytokines [142]. The overall message is that IL6-related cytokines, such as OSM, can affect the efficacy of immune responses towards liver cancer cells, a concept subsequently supported by further studies [141,142]. Finally, it is important to mention an experimental study using the N-diethylnitrosamine (DEN)-induced rat model of HCC, which revealed that the overexpression of OSM significantly increased the number of tumor nodules and shortened rat survival [143]. Moreover, OSM was reported to promote the in vivo activation of hepatic progenitor cells, to induce TNFα secretion and increase the accumulation of CD68-positive macrophages. Accordingly, the depletion of either TNFα or of macrophages is inhibited by the pro-carcinogenic effects of OSM [143]. 5.4. OSM and OSM/OSMRβ in MASH-Related HCC Interest in the specific role of OSM and the OSM/OSMRβ axis in MASH-related HCC is relatively recent. To our knowledge, the first clinical and experimental study to examine OSM in HCC raised in MASH patients was published in 2020 [144]. In this study, the authors analyzed two cohorts of cirrhotic and non-cirrhotic patients carrying HCC having HBV or MASLD/MASH etiology (33 HBV vs. 20 MASLD in cohort 1, 20 HBV vs. 9 MASLD in cohort 2) that were used for different tissue and experimental analyses. This study introduced a novel concept, with data that focused on the role of OSM released by neutrophils infiltrating the tumor mass [144]. This is particularly relevant because neutrophils, although less characterized than tumor-associated macrophages (TAMs) and tumor-infiltrating lymphocytes (TILs), are a significant cellular component in the HCC mass and may contribute to progression [145,146]. In summary, the study identified a relationship between the metabolic switch of macrophages toward aerobic glycolysis and their release of chemokines CXCL2 and CXCL8, which are responsible for the recruitment of neutrophils in the HCC. In addition, activated macrophages release TNFα, which, in turn, stimulate OSM production by neutrophils. This production correlates with HCC metastasis, suggesting, for the first time, OSM as a pro-metastatic mediator in HCC progression [144]. The first clinical and experimental study entirely devoted to investigating the role of OSM in the development and progression of MASH-related HCC was published in 2022 [67]. This study analyzed selected cohorts of MASLD/MASH-related HCC patients, liver cancer cell lines exposed to human recombinant OSM or stably transfected to overexpress human OSM, murine HCC xenografts, and the DEN-CDAA murine MASH-related protocol to induce experimental liver carcinogenesis. Clinically, OSM was selectively overexpressed in HCC cells from MASH patients. Moreover, the analysis of serum levels of OSM in patients, stratified according to the different stages of the disease, revealed that OSM serum levels, barely detectable in patients with steatosis or early steatohepatitis, started to increase in cirrhosis to be then strongly and significantly increased in patients carrying HCC. OSM overexpression is a selective feature of MASH-related HCC: comparing circulating OSM levels in MASH-related HCC patients with those in 51 patients with HCC developed on a different background (HBV, HCV and alcoholic liver disease), serum OSM levels were significantly higher in MASH patients than in those with other etiologies [67]. When MASH-related patients carrying HCC were divided according to the Barcelona Clinic Liver Cancer (BCLC) staging system [147], patients with intermediate or advanced HCC stages (classes B/C/D, respectively) had OSM serum levels significantly higher than those at early stages of HCC with preserved liver function (classes 0/A). Higher serum levels of OSM also correlated with poorer survival. A series of in vitro experiments using liver cancer cell lines indicated OSM overexpression or the exposure to hrOSM resulted in increased angiogenesis as well as in the induction of EMT and invasiveness, indicating that OSM up-regulation in liver cancer cells can contribute to HCC progression. This concept was reinforced by xenograft experiments in which the inoculation of cells overexpressing OSM was associated with a slower tumor growth but a markedly increased and diffuse vascularization of the tumor graft, resulting in an increased rate of lung metastasis. OSM overexpression and its positive correlation with the angiogenic switch were confirmed in the DEN-CDAA model of liver carcinogenesis and the observation that in human MASH-related HCC with vascular invasion, OSM was overexpressed in liver cancer cells invading hepatic vessels. This study also showed that liver cancer cells can both respond to and produce OSM, overall suggesting that the OSM/OSMRβ axis might support HCC progression in MASH patients [67]. In a subsequent study, the role of OSM and the OSM/OSMRβ axis in driving MASH-related HCC progression was investigated using mice carrying a hepatocyte-specific deletion of OSMRβ (hOSMRβ−/− mice), together with in vitro experiments using HCC and immune cell lines and analyses of cohorts of MASH patients, either with or without HCC [83]. hOSMRβ−/− mice were generated by crossing Osmrβ^fl/fl mice on a C57BL/6 background with mice carrying Cre recombinase under the control of the albumin promoter (Alb-Cre), on the same genetic background. The hepatocyte specificity of OSMRβ deletion was confirmed by comparing OSMRβ transcript levels in isolated hepatocytes and hepatic myeloid cells, as well as by assessing OSMRβ transcript and protein levels in the resulting tumors. MASH-related hepatocarcinogenesis was induced in male hOSMRβ−/− and wild-type C57BL/6 mice using the DEN-CDAA protocol. Mice received a single intraperitoneal injection of diethylnitrosamine (DEN; 25 mg/kg body weight) at two weeks of age and, starting at six weeks of age, were fed a choline-deficient, L-amino acid-defined (CDAA) diet for 26 weeks. This protocol combines DEN-mediated tumor initiation with CDAA-induced steatohepatitis and fibrosis, thereby allowing HCC to develop in a MASH-like hepatic microenvironment. Although the model does not reproduce the obesity and systemic insulin resistance typically associated with human MASH, it recapitulates major hepatic features of disease progression, including steatohepatitis, fibrosis and multifocal hepatocarcinogenesis. Two neoplastic nodules from each animal were collected for molecular and histological analyses [86]. Hepatocyte-specific OSMRβ deletion did not affect OSM production by HCCs but significantly reduced the size and weight of hepatic tumors compared with those in wild-type animals subjected to the same protocol, without affecting the overall number of macroscopically detectable nodules. This distinction suggests that hepatocellular OSMRβ signaling primarily promotes the growth and progression of established tumors rather than DEN-dependent tumor initiation. The reduction in tumor burden was associated with decreased levels of proliferation and angiogenesis markers, supporting a causal contribution of autocrine/paracrine OSM/OSMRβ signaling to the growth and vascularization of MASH-related HCC [86]. The use of genetically manipulated mice also revealed that the hepatocyte-specific deletion of the receptor did not affect OSM production by HCC but significantly reduced the size and weight of hepatic tumors compared with those detected in wild-type animals. Moreover, confirming the finding of a previous study [67], the reduction in size and weight of tumors in hOSMRβ−/− mice was associated with a decrease in markers of proliferation (Ki67 and proliferating cell nuclear antigen or PCNA) as well as with a decrease in markers of angiogenesis (VEGFA, VEGF receptor 2 and CD105), indicating that autocrine/paracrine OSM/OSMRβ signaling contributes to MASH-related HCC growth and angiogenesis. The same study subsequently showed an association between OSM expression and the tumor immune microenvironment (TIME) [86]. The hypothesis that OSM may contribute to maintaining the TIME in HCC was first introduced by a clinical study investigating a large cohort (n = 397) of HCC patients of mixed etiologies that underwent surgical resection [147]. Data reported in this study indicated that the majority of patients (n = 248) had a viral etiology (HBV or HCV), whereas for the remaining patients (n = 149), unfortunately, no specific indication of the etiology was reported. Nevertheless, the authors focused their attention on vessels encapsulating tumor cluster (VETC)-positive HCC (n = 62) and VETC negative by analyzing OSM-positive cells and inflammatory/immune cells, including CD4, CD8, CD163 and forkhead box P3 (FOXP3)-positive cells by immunohistochemistry. Data provided indicate that tumor-infiltrating OSM-positive cells were significantly low in VETC-positive HCC. Of interest, in VETC-positive HCC, characterized by a lower grade of hepatocyte differentiation, the number of OSM-positive cells was not associated with vascular invasion, whereas in VETC-negative HCC, an increase in the number of OSM-positive cells was associated with vascular invasion [147]. In a subsequent study, the same group of authors, using the same HCC liver specimens used in the previous article, reported a direct correlation between OSM, tumor CD147 expression and TILs in HCC. Authors proposed this as a mechanism by which CD147 may be able to facilitate HCC immune evasion [148], given that CD147 overexpression has been proposed as a predictor of high malignant potential and advanced clinical stage [149,150]. In this second study, authors investigated the expression of CD147 in liver tumor cells and quantified OSM-positive cells and TILs by using a microarray and immunohistochemistry approach [148]. Interestingly, most of the HCCs investigated had high CD147 expression (n = 332), and in these tumors, the density of OSM-positive cells was associated with CD8, CD4, FOXP3 and CD20-positive cells, whereas, in HCC showing low CD147 expression, OSM positivity was limited to FOXP3-positive cells. The concept of OSM as a mediator potentially involved in reshaping the TIME was confirmed by an analysis of data from the TCGA-LIHC cohort, which includes HCC patients of different etiologies [86] (Figure 3). This analysis identified a significant positive correlation between OSM expression and one of several genes that the literature associates with TIME, such as TAMs and regulatory immune cells markers (CD206, CD163, PD-L1, TGFβ1, CCL22, CCL2, FOXP3, IL2RA, CXCL12, CD33, CD11b, and cyclooxygenase-2). An almost overlapping pattern was detected in HCCs obtained in the liver of mice submitted to the DEN-CDAA protocol of MASH-related carcinogenesis, with OSM expression correlating with either CCL2, TGFβ1, and CXCL12 (i.e., involved in TAMs recruitment) or PD-L1, prostaglandin E synthase 2 (PTGSE2), and CD206 (TAM-associated markers) as well as FOXP3, IL2 receptor antagonist (IL2-RA), CCL22 and CC chemokine receptor (CCR) 4 (markers of regulatory T cells or Treg). Accordingly, all these cytokines, chemokines and markers were significantly down-regulated in HCC from hOSMRβ−/− mice and this pattern was associated with reduced OSM-related signaling (i.e., involving STAT3 phosphorylation) [86]. Finally, a single-cell RNA-seq analysis of human HCCs identified liver cancer cells as the source of the chemokine CCL15, which has been reported to be a putative HCC biomarker associated with immunosuppression in HCCs. Serum levels of CCL15 were strongly up-regulated in both humans and mice carrying MASH-related HCCs, and Kaplan–Meier analysis showed that high CCL15 serum levels were correlated with significantly worse survival of human patients [86]. Moreover, CCL15 serum levels were significantly higher in MASH patients carrying HCCs than in patients carrying HCCs of different etiology. These data are consistent with those previously reported by another research group that suggested CCL15 as a putative HCC biomarker whose expression is significantly correlated with malignant HCC behavior and poor patient survival [151]. Related in vitro studies confirmed that by blocking autocrine OSM signaling in HepG2 or Huh7 cells, overexpressing OSM reduced STAT3 phosphorylation, CCL15 production, and prevented TIME marker expression by co-cultured macrophage-derived THP-1 cells, indicating a direct relationship between OSM and the up-regulation of CCL15. 6. Conclusions Although OSM is also involved in CLD progression and HCC development of different etiologies, OSM and the OSM/OSMRβ axis have an emerging and apparently more relevant role in MASLD/MASH. In concluding this review, we propose that OSM, and the OSM/OSMRβ axis and strictly related mediators, may work differently in relation to the stage and progression of the disease. According to the data and studies mentioned in this review, we propose the following general interpretation in relation to disease progression. Early stages of the disease. Based on some mechanistic studies indicating that OSMRβ deletion may exacerbate early metabolic dysfunction (i.e., steatosis), OSM in the early metabolic stage is likely to act as a context-dependent mediator exerting regulatory, possibly protective action. Disease progression. During disease progression and then in relation to the metabolically related prolonged lipotoxic injury, OSM becomes a pro-inflammatory and profibrogenic mediator capable of contributing significantly to disease progression. Based on the evidence discussed above (see Section 5.2), it seems reasonable to speculate that this dual role of OSM (potentially protective in the early stages but unequivocally pro-inflammatory and pro-fibrogenic in advanced stages) may be closely related to that described for TREM2 CD9-positive macrophages that, during disease progression, turn form protective cells at early stages into pro-inflammatory and profibrogenic cells. This specific aspect should be further and carefully investigated in future studies. MASH-related HCC. Increased OSM expression is emerging as a particularly relevant feature of HCC with a metabolic etiology and correlates with clinical parameters and disease outcomes. Data from patients and murine studies as well as from in vitro studies suggest that OSM and its signaling have a pro-angiogenic role and can efficiently sustain the proliferation, EMT and increased invasiveness of liver cancer cells. Moreover, OSM is now suggested to have a role in reshaping TIME and then favoring immune evasion of cancer cells in HCC. This promising and clinically relevant hypothesis should be tested in the future to validate the synergy between OSM inhibition and ICI efficacy. Overall, OSM can be proposed as a candidate biomarker and a putative therapeutic target for MASH-related HCC. The most relevant pre-clinical and clinical data supporting the involvement of OSM and the OSM/OSMRβ axis in CLD, MASLD/MASH and HCC cited in this review are summarized in Table 1.